Dillman RO, et al. - In a randomized phase II trial, researchers compared autologous tumor cell vaccines (TCV) and autologous dendritic cell vaccines (DCV) loaded with autologous tumor-associated antigens (TAA). DCV was shown to be related to minimal toxicity and long-term survival in patients with metastatic melanoma. For survival prognostication as well as for prediction of benefit for either vaccine, there was no role of delayed-type hypersensitivity (DTH) to autologous tumor cells. This is the only human clinical trial comparing DCV and TCV as platforms for autologous TAA presentation.